{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T22:00:37Z","timestamp":1777327237284,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,24]]},"DOI":"10.7759\/cureus.34169","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T02:22:21Z","timestamp":1674613341000},"source":"Crossref","is-referenced-by-count":7,"title":["Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study"],"prefix":"10.7759","author":[{"given":"Remi K","family":"Hamel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cailin","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Mann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.09.058","article-title":"Primary cicatricial alopecia: Lymphocytic primary cicatricial alopecias, including chronic cutaneous lupus erythematosus, lichen planopilaris, frontal fibrosing alopecia, and Graham-Little syndrome","volume":"75","author":"Bolduc C","year":"2016","unstructured":"Bolduc C, Sperling LC, Shapiro J. Primary cicatricial alopecia: Lymphocytic primary cicatricial alopecias, including chronic cutaneous lupus erythematosus, lichen planopilaris, frontal fibrosing alopecia, and Graham-Little syndrome. J Am Acad Dermatol. 2016, 75:1081-99. 10.1016\/j.jaad.2014.09.058","journal-title":"J Am Acad Dermatol"},{"key":"ref2","article-title":"Novel treatment using low-dose naltrexone for lichen planopilaris","volume":"16","author":"Strazzulla LC","year":"2017","unstructured":"Strazzulla LC, Avila L, Lo Sicco K, Shapiro J. Novel treatment using low-dose naltrexone for lichen planopilaris. J Drugs Dermatol. 2017, 16:1140-2.","journal-title":"J Drugs Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.10.025","article-title":"Commentary: treatment of lichen planopilaris: some progress, but a long way to go","volume":"62","author":"Sperling LC","year":"2010","unstructured":"Sperling LC, Nguyen JV. Commentary: treatment of lichen planopilaris: some progress, but a long way to go. J Am Acad Dermatol. 2010, 62:398-401. 10.1016\/j.jaad.2009.10.025","journal-title":"J Am Acad Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.08.054","article-title":"Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system","volume":"62","author":"Chiang C","year":"2010","unstructured":"Chiang C, Sah D, Cho BK, Ochoa BE, Price VH. Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system. J Am Acad Dermatol. 2010, 62:387-92. 10.1016\/j.jaad.2009.08.054","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S177308","article-title":"Frontal fibrosing alopecia: efficacy of treatment modalities","volume":"11","author":"Gamret AC","year":"2019","unstructured":"Gamret AC, Potluri VS, Krishnamurthy K, Fertig RM. Frontal fibrosing alopecia: efficacy of treatment modalities. Int J Womens Health. 2019, 11:273-85. 10.2147\/IJWH.S177308","journal-title":"Int J Womens Health"},{"key":"ref6","article-title":"Low dose naltrexone in dermatology","volume":"18","author":"Jaros J","year":"2019","unstructured":"Jaros J, Lio P. Low dose naltrexone in dermatology. J Drugs Dermatol. 2019, 18:235-8.","journal-title":"J Drugs Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.12.031","article-title":"The uses of naltrexone in dermatologic conditions","volume":"80","author":"Lee B","year":"2019","unstructured":"Lee B, Elston DM. The uses of naltrexone in dermatologic conditions. J Am Acad Dermatol. 2019, 80:1746-52. 10.1016\/j.jaad.2018.12.031","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.4093","article-title":"Utility of naltrexone treatment for chronic inflammatory dermatologic conditions: a systematic review","volume":"155","author":"Ekelem C","year":"2019","unstructured":"Ekelem C, Juhasz M, Khera P, Mesinkovska NA. Utility of naltrexone treatment for chronic inflammatory dermatologic conditions: a systematic review. JAMA Dermatol. 2019, 155:229-36. 10.1001\/jamadermatol.2018.4093","journal-title":"JAMA Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2174\/1389450120666190318121122","article-title":"The use of naltrexone in dermatology; current evidence and future directions","volume":"20","author":"Sikora M","year":"2019","unstructured":"Sikora M, Rakowska A, Olszewska M, Rudnicka L. The use of naltrexone in dermatology; current evidence and future directions. Curr Drug Targets. 2019, 20:1058-67. 10.2174\/1389450120666190318121122","journal-title":"Curr Drug Targets"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.079","article-title":"Medical therapy for frontal fibrosing alopecia: a review and clinical approach","volume":"81","author":"Ho A","year":"2019","unstructured":"Ho A, Shapiro J. Medical therapy for frontal fibrosing alopecia: a review and clinical approach. J Am Acad Dermatol. 2019, 81:568-80. 10.1016\/j.jaad.2019.03.079","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.043","article-title":"Algorithmic approach to the treatment of frontal fibrosing alopecia: a systematic review","volume":"85","author":"Dina Y","year":"2021","unstructured":"Dina Y, Aguh C. Algorithmic approach to the treatment of frontal fibrosing alopecia: a systematic review. J Am Acad Dermatol. 2021, 85:508-10. 10.1016\/j.jaad.2018.10.043","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5070\/D3258045142","article-title":"Low-dose naltrexone: a novel adjunctive treatment in symptomatic alopecias?","volume":"25","author":"Tortelly VD","year":"2019","unstructured":"Tortelly VD, De Mattos T, Fernandes LSA, Nunes BEM, Melo DF. Low-dose naltrexone: a novel adjunctive treatment in symptomatic alopecias?. Dermatol Online J. 2019, 25:12 . 10.5070\/D3258045142","journal-title":"Dermatol Online J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1774488","article-title":"The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled clinical trial","volume":"33","author":"Lajevardi V","year":"2022","unstructured":"Lajevardi V, Salarvand F, Ghiasi M, Nasimi M, Taraz M. The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled clinical trial. J Dermatolog Treat. 2022, 33:769-73. 10.1080\/09546634.2020.1774488","journal-title":"J Dermatolog Treat"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0359","article-title":"Association of inflammation with progression of hair loss in women with frontal fibrosing alopecia","volume":"156","author":"Saceda-Corralo D","year":"2020","unstructured":"Saceda-Corralo D, Pindado-Ortega C, Moreno-Arrones OM, Ortega-Quijano D, Fern\u00e1ndez-Nieto D, Jim\u00e9nez-Cauhe J, Va\u00f1\u00f3-Galv\u00e1n S. Association of inflammation with progression of hair loss in women with frontal fibrosing alopecia. JAMA Dermatol. 2020, 156:700-2. 10.1001\/jamadermatol.2020.0359","journal-title":"JAMA Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7753.125616","article-title":"Perifollicular erythema as a trichoscopy sign of progression in frontal fibrosing alopecia","volume":"5","author":"Toledo-Pastrana T","year":"2013","unstructured":"Toledo-Pastrana T, Hern\u00e1ndez MJ, Camacho Mart\u00ednez FM. Perifollicular erythema as a trichoscopy sign of progression in frontal fibrosing alopecia. Int J Trichology. 2013, 5:151-3. 10.4103\/0974-7753.125616","journal-title":"Int J Trichology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000487158","article-title":"Frontal fibrosing alopecia severity index: a trichoscopic visual scale that correlates thickness of peripilar casts with severity of inflammatory changes at pathology","volume":"4","author":"Mart\u00ednez-Velasco MA","year":"2018","unstructured":"Mart\u00ednez-Velasco MA, V\u00e1zquez-Herrera NE, Misciali C, Vincenzi C, Maddy AJ, Asz-Sigall D, Tosti A. Frontal fibrosing alopecia severity index: a trichoscopic visual scale that correlates thickness of peripilar casts with severity of inflammatory changes at pathology. Skin Appendage Disord. 2018, 4:277-80. 10.1159\/000487158","journal-title":"Skin Appendage Disord"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.09.034","article-title":"Development and validation of the frontal fibrosing alopecia severity score","volume":"78","author":"Saceda-Corralo D","year":"2018","unstructured":"Saceda-Corralo D, Moreno-Arrones \u00d3M, Fonda-Pascual P, et al.. Development and validation of the frontal fibrosing alopecia severity score. J Am Acad Dermatol. 2018, 78:522-9. 10.1016\/j.jaad.2017.09.034","journal-title":"J Am Acad Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.067","article-title":"Inexpensive compounding of low-dose naltrexone (LDN) with orange juice","volume":"85","author":"Bronfenbrener R","year":"2021","unstructured":"Bronfenbrener R. Inexpensive compounding of low-dose naltrexone (LDN) with orange juice. J Am Acad Dermatol. 2021, 85:e139. 10.1016\/j.jaad.2019.03.067","journal-title":"J Am Acad Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1242-0","article-title":"Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis","volume":"17","author":"Bolton M","year":"2019","unstructured":"Bolton M, Hodkinson A, Boda S, et al.. Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis. BMC Med. 2019, 17:10. 10.1186\/s12916-018-1242-0","journal-title":"BMC Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr070105","article-title":"The decrease in breast-cancer incidence in 2003 in the United States","volume":"356","author":"Ravdin PM","year":"2007","unstructured":"Ravdin PM, Cronin KA, Howlader N, et al.. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007, 356:1670-4. 10.1056\/NEJMsr070105","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2174\/2589977513666210127094222","article-title":"Low doses naltrexone: the potential benefit effects for its use in patients with cancer","volume":"13","author":"Couto RD","year":"2021","unstructured":"Couto RD, Fernandes BJ. Low doses naltrexone: the potential benefit effects for its use in patients with cancer. Curr Drug Res Rev. 2021, 13:86-9. 10.2174\/2589977513666210127094222","journal-title":"Curr Drug Res Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.07.035","article-title":"Prognosis, treatment, and disease outcomes in frontal fibrosing alopecia: a retrospective review of 92 cases","volume":"78","author":"Strazzulla LC","year":"2018","unstructured":"Strazzulla LC, Avila L, Li X, Lo Sicco K, Shapiro J. Prognosis, treatment, and disease outcomes in frontal fibrosing alopecia: a retrospective review of 92 cases. J Am Acad Dermatol. 2018, 78:203-5. 10.1016\/j.jaad.2017.07.035","journal-title":"J Am Acad Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00424-y","article-title":"Frontal fibrosing alopecia: an update on pathogenesis, diagnosis, and treatment","volume":"20","author":"Iorizzo M","year":"2019","unstructured":"Iorizzo M, Tosti A. Frontal fibrosing alopecia: an update on pathogenesis, diagnosis, and treatment. Am J Clin Dermatol. 2019, 20:379-90. 10.1007\/s40257-019-00424-y","journal-title":"Am J Clin Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.062","article-title":"Updated diagnostic criteria for frontal fibrosing alopecia","volume":"78","author":"Va\u00f1\u00f3-Galv\u00e1n S","year":"2018","unstructured":"Va\u00f1\u00f3-Galv\u00e1n S, Saceda-Corralo D, Moreno-Arrones \u00d3M, Camacho-Martinez FM. Updated diagnostic criteria for frontal fibrosing alopecia. J Am Acad Dermatol. 2018, 78:e21-2. 10.1016\/j.jaad.2017.08.062","journal-title":"J Am Acad Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.09.027","article-title":"Reply to: \"updated diagnostic criteria for frontal fibrosing alopecia\"","volume":"78","author":"Tolkachjov SN","year":"2018","unstructured":"Tolkachjov SN, Chaudhry HM, Imhof RL, Camilleri MJ, Torgerson RR. Reply to: \"updated diagnostic criteria for frontal fibrosing alopecia\". J Am Acad Dermatol. 2018, 78:e23-4. 10.1016\/j.jaad.2017.09.027","journal-title":"J Am Acad Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/132544-oral-low-dose-naltrexone-in-the-treatment-of-frontal-fibrosing-alopecia-and-lichen-planopilaris-an-uncontrolled-open-label-prospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:56:18Z","timestamp":1707508578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/132544-oral-low-dose-naltrexone-in-the-treatment-of-frontal-fibrosing-alopecia-and-lichen-planopilaris-an-uncontrolled-open-label-prospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.34169","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,24]]}}}